These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 4450660)

  • 61. Low-dose intermittent urokinase therapy in chronic symptomatic end-stage arterial disease--clinical relevance for patients with coronary artery disease or peripheral arterial occlusive disease.
    Leschke M; Schoebel FC; Strauer BE
    Clin Hemorheol Microcirc; 1997; 17(1):59-66. PubMed ID: 9181759
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Pharmacological impact of snake venom compounds.
    Marcinkiewicz C
    Curr Pharm Des; 2007; 13(28):2851-2. PubMed ID: 17979729
    [No Abstract]   [Full Text] [Related]  

  • 63. Exploring snake venom proteomes: multifaceted analyses for complex toxin mixtures.
    Fox JW; Serrano SM
    Proteomics; 2008 Feb; 8(4):909-20. PubMed ID: 18203266
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Fibrinogen-fibrin derivatives during difibrase therapy. Detection and course observations of high-molecular and low-molecular derivatives using agarose gel filtration].
    Asbeck F; Lechler E; van de Loo J
    Verh Dtsch Ges Inn Med; 1974; 80():1466-70. PubMed ID: 4454459
    [No Abstract]   [Full Text] [Related]  

  • 65. Characterization of hyaluronidase isolated from Agkistrodon contortrix contortrix (Southern Copperhead) venom.
    Kudo K; Tu AT
    Arch Biochem Biophys; 2001 Feb; 386(2):154-62. PubMed ID: 11368337
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Intra-arterial administration of penicillin and vasodilating agents in occlusive diseases of the peripheral arteries].
    Hubl S; Wesolowski J
    Pol Tyg Lek; 1973 Jul; 28(30):1150-1. PubMed ID: 4732712
    [No Abstract]   [Full Text] [Related]  

  • 67. [Improvement of walking disability and conservative treatment. Guiding principles for drug treatment of chronic arterial occlusive disease (stage I and IIb)].
    Heinrich F
    Fortschr Med; 1984 Sep; 102(36):74-5. PubMed ID: 6489898
    [No Abstract]   [Full Text] [Related]  

  • 68. Clinical trial of intramuscular anti-snake venom administration as a first aid measure in the field in the management of Russell's viper bite patients.
    Win-Aung ; Tin-Tun ; Khin-Maung-Maung ; Aye-Kyaw ; Hla-Pe ; Tin-Nu-Swe ; Saw-Naing
    Southeast Asian J Trop Med Public Health; 1996 Sep; 27(3):494-7. PubMed ID: 9185259
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Practical applications of snake venom toxins in haemostasis.
    Marsh N; Williams V
    Toxicon; 2005 Jun; 45(8):1171-81. PubMed ID: 15922782
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The anti-snake venom activities of the methanolic extract of the bulb of Crinum jagus (Amaryllidaceae).
    Ode OJ; Asuzu IU
    Toxicon; 2006 Sep; 48(3):331-42. PubMed ID: 16890262
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Rheologic therapy of peripheral arteriopathies. Personal observations on the use of flunarizin].
    Palleschi M; Marci M; Ceraso C; Passacantilli A; Marin P
    Clin Ter; 1984 Aug; 110(3):215-20. PubMed ID: 6237860
    [No Abstract]   [Full Text] [Related]  

  • 72. Histopathological changes induced by the venom of the snake Vipera raddei (Armenian adder).
    Aznaurian AV; Amiryan SV
    Toxicon; 2006 Feb; 47(2):141-3. PubMed ID: 16373073
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Proteome analysis of snake venom toxins: pharmacological insights.
    Georgieva D; Arni RK; Betzel C
    Expert Rev Proteomics; 2008 Dec; 5(6):787-97. PubMed ID: 19086859
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Increased radiation resistance of mice injected with bee venom one day prior to exposure. USNRDL-TR-67-4.
    Shipman WH; Cole LJ
    Res Dev Tech Rep; 1967 Jan; ():1-10. PubMed ID: 5298216
    [No Abstract]   [Full Text] [Related]  

  • 75. The modification of experimental occlusive arterial thrombosis in the rat by Malayan pit viper venom.
    Chan KE
    Thromb Diath Haemorrh; 1968 Mar; 19(1):242-7. PubMed ID: 5652231
    [No Abstract]   [Full Text] [Related]  

  • 76. Flurry over venom.
    Holden C
    Science; 1980 Jan; 207(4427):161. PubMed ID: 7350649
    [No Abstract]   [Full Text] [Related]  

  • 77. Advances in Usage of Venom Proteins as Diagnostics and Therapeutic Mediators.
    Khan S
    Protein Pept Lett; 2018; 25(7):610-611. PubMed ID: 30303047
    [No Abstract]   [Full Text] [Related]  

  • 78. Snake venom: a potent anticancer agent.
    Jain D; Kumar S
    Asian Pac J Cancer Prev; 2012; 13(10):4855-60. PubMed ID: 23244070
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Snake charmer needed to soothe this debate.
    Gunby P
    JAMA; 1980 Dec; 244(22):2496. PubMed ID: 7431579
    [No Abstract]   [Full Text] [Related]  

  • 80. [Therapy of arterial occlusive diseases with Dusodril].
    Fortschr Med; 1974 Jul; 92(20):873-4. PubMed ID: 4411256
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.